地西他滨联合CAG治疗TET2阳性老年急性髓细胞白血病的疗效观察

Effect of Decitabine Combined with CAG on TET2 Positive Senile Acute Myeloid Leukemia

目的:研究地西他滨联合CAG(盐酸阿柔比星+阿糖胞苷+粒细胞集落刺激因子)治疗TET2阳性老年急性髓细胞白血病(acute myelocytic leukemia,AML)的效果。方法:选取2013年1月-2020年9月本院收治的46例TET2阳性老年AML患者,其中2013年1月-2018年1月TET2阳性老年AML患者23例为对照组实行CAG方案,2018年6月-2020年9月TET2阳性老年AML患者23例为观察组实行地西他滨+CAG方案,比较两组疗效。结果:用药后,两组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)指标均降低,且观察组均低于对照组,差异均有统计学意义(P<0.05)。观察组总有效率较对照组更高,差异有统计学意义(P<0.05)。两组白细胞恢复时间、血小板输注量比较,差异均无统计学意义(P>0.05)。两组各项不良反应率比较,差异均无统计学意义(P>0.05)。结论:地西他滨联合CAG方案治疗TET2阳性老年AML患者能提高疗效,不会增加不良反应,值得推广。

Objective:To study effect of Decitabine combined with CAG(Arubicin Hydrochloride+Cytara Bine+granulocyte colony stimulating factor)on TET2 positive senile acute myeloid leukemia(AML).Method:A total of 46 elderly patients with TET2 positive AML admitted to our hospital from January 2013 to September 2020 were selected.Among them,23 elderly patients with TET2 positive AML from January 2013 to January 2018 were treated with CAG scheme in the control group,and 23 elderly patients with TET2 positive AML from June 2018 to September 2020 were treated with Decitabine+CAG scheme in the observation group.The efficacy of the two groups was compared.Result:After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)indexes were decreased in both groups,and the observation group of those were lower than those in the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There were no significant differences in WBC recovery time and platelet infusion volume between the two groups(P>0.05).There was no statistical significance in adverse reaction rates between the two groups(P>0.05).Conclusion:Decitabine+CAG regimen in the treatment of TET2 positive elderly AML patients can improve the efficacy,can’t increase adverse reactions,which is worthy of praise.